Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

Part of paid clinical trials in Livonia, Michigan.

Sponsor
Oculis
Study ID
NCT07623668
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Optic Neuritis

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Privosegtor — DRUG
    Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days
  • Methylprednisolone — DRUG
    Methylprednisolone 1 g/day IV for 5 treatment days
  • Placebo — OTHER
    0.9% sodium chloride (NaCl) solution IV for 5 treatment days

Study Details

The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).

Key Dates

First listed
Jun 3, 2026
Start date
May 28, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
210 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Privosegtor
  • Placebo Comparator: Placebo

Primary Outcome Measure

Proportion of participants achieving at least 15-letter gain from baseline in low contrast visual acuity (LCVA). [ Time Frame: 3 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Kahana Oculoplastic and Orbital SurgeryLivoniaMichigan48152
Dr. Victoria Williams
[email protected]
248-800-1177
Neuro-Eye Clinical TrialsHoustonTexas77074
Mirna Maldonado
[email protected]
713-894-4393

Find similar trials in Livonia, MI

By research site
Kahana Oculoplastic and Orbital Surgery· Livonia, MINeuro-Eye Clinical Trials· Houston, TX

Related Studies